Search research articles
Contact Us
Filters
Showing results (51-60 of 55) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 55 results.
Clinical and Translational Radiation Oncology
|
August 30, 2021
Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
Wei Wang, Jessica Louise Smith, Matteo Salvatore Carlino, et al.
Haematologica
|
April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)
Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
Pediatric Neurology
|
May 11, 2020
Phenotypic and Imaging Spectrum Associated With WDR45
Laura A Adang, Amy Pizzino, Alka Malhotra, et al.
Leukemia
|
February 7, 2020
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
C Ola Landgren, Ajai Chari, Yael C Cohen, et al.
Lancet (London, England)
|
June 16, 2009
Professionals Against Child Abuse express support for David Southall
Damian Armstrong, John Bridson, Margaret Crawford, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 55) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 55 results.
Clinical and Translational Radiation Oncology
|
August 30, 2021
Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
Wei Wang, Jessica Louise Smith, Matteo Salvatore Carlino, et al.
Haematologica
|
April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)
Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
Pediatric Neurology
|
May 11, 2020
Phenotypic and Imaging Spectrum Associated With WDR45
Laura A Adang, Amy Pizzino, Alka Malhotra, et al.
Leukemia
|
February 7, 2020
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
C Ola Landgren, Ajai Chari, Yael C Cohen, et al.
Lancet (London, England)
|
June 16, 2009
Professionals Against Child Abuse express support for David Southall
Damian Armstrong, John Bridson, Margaret Crawford, et al.
Page
of 6